Genmab: benefits from FDA's approval of Darzalex
(CercleFinance.com) - The Genmab share is in demand in Copenhagen on Friday following the FDA's approval for the marketing of Darzalex in the treatment of relapsed or refractory multiple myeloma.
The stock is currently up around 1%, outperforming the OMXN40 benchmark index of the Nordic stock markets, which is up 0.4%.
The FDA yesterday approved Darzalex for use in combination with the standard treatment of carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have exhausted other approved treatment lines.
Darzalex - which leads to rapid tumor cell death by apoptosis (programmed cell death) - is marketed by Janssen, a subsidiary of Johnson & Johnson, since the signing of a licensing agreement in 2012 with Genmab, which receives royalties on product sales.
Copyright (c) 2020 CercleFinance.com. All rights reserved.